OSE IMMUNO: Anticipating another out-licensing deal, albeit the delays in clinical studies as well | CORPORATE | EUR7(+101%)
OSE IMMUNO - CORPORATE | EUR7(+101%)Anticipating another out-licensing deal, albeit the delays in clinical studies as well
Strong cash position provides financial visibility until 1Q21
More clarity on Atalante-1 status in coming weeks
Delays in recruitment, although still expecting early milestone
Anticipating FR104 out-licensing deal in 2H20 – 1H21
Ose Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company principally engaged in the clinical stage biotechnological sector. The Company develops immunotherapy products against invasive or metastatic late-stage cancers. The Company offers a technology, called Memopi, which helps the immune system to eliminate malignant cells; it re-educates the body's immunological memory so that the immune system (and particularly T cytotoxic cells) attacks tumor cells by increasing the patient's specific cytotoxic T response against their cancer. The Company's main product, Texopi, is a patented combination of ten epitopes, selected and optimized from five tumor associated antigens.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.